Stock·NYSE·Technology
Oracle Corporation (ORCL)
- Market cap
- $388.73B
- P/E
- 23.10
- Dividend yield
- 1.56%
- Street target
- $240.00median of 43 analysts
- 52-week range
- $114.50 $289.24
The short version
Where ORCL stands today, in four lines, and what CleaRank Financial AI makes of it.
ORCL at a glance
Oracle Corporation (ORCL): Hold, 51/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($145.12 and $160.19).
- Earnings ORCL beat estimates in 5 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $2.1B and bought $3.6M over the last 18 months.
- Valuation P/E of 23.1 against 35.1 for the Technology sector: a discount to peers (-34%).
Figures as of October 18, 2026.
CleaRank Financial AI
CleaRank rates Oracle Corporation (ORCL) Hold, with a model score of 51/100.
The analysts' outlook lifts the score most: 35 of 43 analysts rate it a buy and the median target is 87.2% above the price. The trend holds it back most: the price is 19.95% below its 200-day average and 11.64% below its 50-day average, and the 50-day average is 9.41% below the 200-day. The 50-day average stands at $145.12 and the 200-day at $160.19. Over the past year the price fell 59.03%.
Only on CleaRank
Figures we compute ourselves from ORCL's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $128.23 is 11.6% below the 50-day simple moving average of $145.12.Price above its 200-day average ›
The price is 20.0% below the 200-day simple moving average of $160.19.50-day average above the 200-day ›
The 50-day average ($145.12) is 9.4% below the 200-day average ($160.19), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 8% of its 52-week range, between $114.50 and $289.24.
ORCL share price
Pick a period: each tab shows how far ORCL has moved over it, to the last close.
Today's trading
Where ORCL sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 23.10 is 34.2% below the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 5.68 is 25.3% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $18.7B on revenue of $71.8B, a net margin of 26.1%.Beat estimates in most recent reports ›
ORCL beat the EPS estimate in 5 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 1.56%, or $2.00 a share a year.
Key statistics
The headline figures for ORCL.
As of October 18, 2026, ORCL trades at $128.23, with a market value of $388.73B, a P/E ratio of 23.10 and a dividend yield of 1.56%.
What the numbers say
CleaRank Financial AI's reading of ORCL's valuation, growth and risks.
Oracle Corporation (ORCL) trades on a trailing P/E of 23.10, against a Technology median of 35.1. That leaves it 34.2% below the sector, a discount to peers by the peer comparison on this page. On sales, ORCL's P/S of 5.68 is 25.3% below the sector median of 7.6. Its trailing earnings stand at $5.82 a share.
ORCL's revenue grew 29.60%, which is 5.4 percentage points faster than the sector median of 24.2%. Profitability is strong too: a net margin of 26.36% and an operating margin of 35.63% sit alongside a return on equity of 41.19%, which is above the sector median of 13.4%. On the balance sheet, debt-to-equity stands at 2.52, and the trailing dividend yield is 1.56%, equal to $2.00 per share each year.
The September 10, 2026 report delivered EPS of $1.92, beating the $1.74 analysts had expected by 10.34%. Even so, the stock slipped 1.74% in the next session.
ORCL has beaten estimates in 5 of the last 8 reports, yet a beat has not reliably lifted the shares: the stock fell the next session after 3 of those 5 beats. For this fiscal year, analysts average an EPS estimate of $8.14, a change of 6.7%, and they see $11.00 next year, growth of 35.1%.
The 30-day standard deviation of ORCL's daily returns is 3.37%. Until the price regains its moving averages, the trend works against holders. The price is 55.67% below its 52-week high of $289.24. Insiders sold $2.1B over the last 18 months and bought $3.6M, though sales of this kind are often planned in advance and say less than purchases would.
ORCL against the Technology sector
How ORCL compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: ORCL trades at a notable discount to sector peers (-34%), which may indicate undervaluation or specific company headwinds.
Return vs XLK: Since May 6, 2025, ORCL has lost 13.2% against a gain of 71.7% for XLK.
Performance against XLK
ORCL and the Technology sector fund over the same days.
Revenue and earnings
How much ORCL sells, and how much of it becomes profit.
Revenue growth: Revenue grew 17.3% in FY2026 to $67.4B, from $57.4B a year earlier.
Profit margin: The net margin was 25.4% in FY2026, up from 21.7% the year before.
Profitable: ORCL earned $17.1B in FY2026.
Earnings reality check
Did ORCL beat what analysts expected, and how did the stock react?
Earnings record: ORCL beat the analyst estimate in 5 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Sep 10, 2026after close | $1.74 | $1.92 | +10.34% | -1.74% | -1.54% |
| Jun 10, 2026after close | $1.96 | $2.11 | +7.65% | -8.53% | -8.81% |
| Mar 10, 2026after close | $1.69 | $1.79 | +5.92% | +9.18% | +3.54% |
| Dec 10, 2025after close | $1.64 | $2.26 | +37.80% | -10.83% | -19.98% |
| Sep 9, 2025after close | $1.48 | $1.47 | -0.68% | +35.95% | +26.97% |
| Jun 11, 2025after close | $1.64 | $1.70 | +3.66% | +13.31% | +19.55% |
| Mar 10, 2025after close | $1.49 | $1.47 | -1.34% | -3.10% | +3.51% |
| Dec 9, 2024after close | $1.48 | $1.47 | -0.68% | -6.67% | -10.09% |
As of October 18, 2026, ORCL has beaten the analyst EPS estimate in 5 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on September 10, 2026, came in 10.34% above the estimate and the stock moved -1.74% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 39.7, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 39.7 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of ORCL
The score, the reasoning behind it, and what could move the price next.
ORCL's trend is down: the price of $128.23 sits 19.95% below its 200-day average of $160.19 and 11.64% below its 50-day average of $145.12. Near the bottom of its 52-week range, the price is 11.99% above the low of $114.50 and 55.67% below the high of $289.24.
ORCL's 14-day RSI of 39.7 sits in the bearish zone without reaching oversold territory, and the MACD line is negative. The two time frames disagree: over the past month the price dropped 10.43%, while over the past three months it climbed 1.44%, and across the past year it slid 59.03%.
Earnings beat ›
The September 10, 2026 report beat the EPS estimate by 10.34%, and the share price fell 1.74% in the first session after it.
Source: Earnings report, September 10, 2026
Rating reaffirmed ›
Citizens kept its Market Outperform rating on October 2, 2026.
Source: Analyst action, Citizens, October 2, 2026
- The two nearest levels to watch are the 20-day EMA at $139.17, above the price, and the 52-week low at $114.50, below it.
- With the 14-day RSI at 39.7, momentum falls in the bearish zone and the MACD line is negative. Stretched momentum would show up as readings above 70 or below 30.
- The share price fell 1.74% in the first session after the September 10, 2026 report. Over the last 8 reports, ORCL beat estimates in 5.
ORCL is priced below its 50-day and 200-day moving averages ($145.12 and $160.19), and that combination is why the trend reads as down. A move back above the 50-day would be the first sign of the trend mending. Above the price, the first level to watch is the 20-day EMA at $139.17.
The next level below the price is the 52-week low at $114.50. With the RSI in the bearish zone, momentum still leans lower.
Technical indicators
Momentum and trend for ORCL, from its daily closes.
As of October 18, 2026, with ORCL at $128.23, its 14-day RSI is 39.7 (showing bearish momentum without being oversold), its 50-day simple moving average is $145.12 and its 200-day is $160.19.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ORCL moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, ORCL's 1-year correlation of daily returns is +0.49 with S&P 500 (SPY), +0.52 with Nasdaq 100 (QQQ), +0.33 with Bitcoin (BTC) and +0.13 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
35 of 43 analysts rate it a buy or strong buy, 7 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $240.00 is 87.2% above the price.More buy ratings than three months ago ›
35 of 43 rate it a buy now, against 37 of 44 three months ago.
ORCL Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 2, 2026 | Citizens | Reiterates | Market Outperform |
| Sep 14, 2026 | Freedom Broker | Maintains | Buy |
| Sep 14, 2026 | Argus Research | Reiterates | Buy |
| Sep 11, 2026 | Stifel | Maintains | Buy |
| Sep 11, 2026 | TD Cowen | Reiterates | Buy |
| Sep 11, 2026 | UBS | Maintains | Buy |
As of October 18, 2026, 43 Wall Street analysts cover ORCL: 35 rate it a buy or strong buy, 7 a hold and 1 a sell or strong sell. Their 12-month price targets range from $110.00 to $400.00, with a median of $240.00, 87.2% above the price of $128.23.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ORCL trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
ORCL moves about 3.4% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ORCL tends to move, against the market and on its own.
The long record
ORCL's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 3.37% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 63.0%, from September 2025 to July 2026; the price is still 60.4% below that peak.Most 1-year holds ended higher ›
79% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $38,708, against $41,793 in the S&P 500 (SPY).
ORCL Drawdowns & Recovery
As of October 18, 2026, ORCL's worst peak-to-trough fall over the last 10 years with dividends reinvested was -63.0% (September 2025 to July 2026); it is still 60.4% below that peak, and 79% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ORCL in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ORCL trailed the S&P 500 over this period: $38,708 against $41,793.
A $10,000 investment in ORCL in October 2016 would be worth about $38,708 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ORCL, and which have not.
Strongest month, May: an average of +6.00%, up in 7 of 10 years.
Weakest month, December: an average of -3.90%, up in 1 of 10 years.
This month, October: has averaged +1.14%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ORCL's strongest calendar month has been May (average +6.00%, up in 7 of 10 years) and its weakest December (average -3.90%, up in 1 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ORCL, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ORCL today could grow to about $22,920 by 2036 in the base case, with a 90th-percentile outcome near $98,203 and a 10th-percentile outcome around $5,349. The simulation models price only; at today's 1.56% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ORCL Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $179 for ORCL by 2030 in the base case, from $128 today (1.4x over 4 years). The 10th-percentile path ends near $71.19. These are outcomes of a Monte Carlo simulation run on ORCL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $87.94 | $139 | $221 | |
| 2028 | $78.96 | $151 | $290 | |
| 2029 | $74.12 | $164 | $365 | |
| 2030 | $71.19 | $179 | $448 | |
| 2031 | $69.38 | $194 | $543 |
Method: a lognormal simulation of ORCL's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
ORCL insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $3.6M on the open market and sold $2.1B.
As of October 18, 2026, ORCL insiders reported 30 open-market sales worth $2.1B and 2 open-market purchases worth $3.6M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Stephen H Rusckowski
Director
|
Buy | 25.0K | $3.5M |
| Sep 22, 2026 | Michael D Sicilia
Chief Executive Officer
|
Sell | 22.6K | $3.4M |
| Sep 22, 2026 | Maria Smith
Officer
|
Sell | 2.6K | $399.1K |
| Sep 18, 2026 | Jeffrey O Henley
Officer and Director
|
Grant | 46.5K | - |
| Sep 18, 2026 | Mark Hura
Officer
|
Grant | 67.1K | - |
| Sep 18, 2026 | Stuart A Levey
Officer
|
Grant | 20.9K | - |
| Sep 18, 2026 | Clayton M Magouyrk
Chief Executive Officer
|
Grant | 129.9K | - |
| Sep 18, 2026 | Michael D Sicilia
Chief Executive Officer
|
Grant | 109.2K | - |
| Sep 18, 2026 | Maria Smith
Officer
|
Grant | 17.4K | - |
| Sep 16, 2026 | Michael D Sicilia
Chief Executive Officer
|
Sell | 10.9K | $1.5M |
| Sep 15, 2026 | Michael D Sicilia
Chief Executive Officer
|
Grant | 52.7K | - |
| Jun 24, 2026 | Jeffrey O Henley
Officer and Director
|
Sell | 400.0K | $63.7M |
| Jun 24, 2026 | Jeffrey O Henley
Officer and Director
|
Option | 400.0K | $16.4M |
| May 29, 2026 | Awo Ablo
Director
|
Grant | 2.1K | - |
| May 29, 2026 | Jeffrey S Berg
Director
|
Grant | 2.1K | - |
| May 29, 2026 | Michael J Boskin
Director
|
Grant | 2.1K | - |
| May 29, 2026 | Bruce R Chizen
Director
|
Grant | 2.1K | - |
| May 29, 2026 | Rona Alison Fairhead
Director
|
Grant | 2.1K | - |
| May 29, 2026 | Charles W Moorman IV
Director
|
Grant | 2.1K | - |
| Apr 16, 2026 | Stuart A Levey
Officer
|
Sell | 15.0K | $2.6M |
| Mar 30, 2026 | Jeffrey O Henley
Officer and Director
|
Grant | 16.8K | - |
| Feb 9, 2026 | Clayton M Magouyrk
Chief Executive Officer
|
Sell | 10.0K | $1.6M |
| Jan 15, 2026 | Douglas A Kehring
Officer
|
Sell | 35.0K | $6.8M |
| Dec 24, 2025 | Mark Hura
Officer
|
Sell | 15.0K | $3.0M |
| Dec 23, 2025 | Naomi O Seligman
Director
|
Sell | 2.2K | $437.1K |
| Dec 22, 2025 | Mark Hura
Officer
|
Grant | 5.0K | - |
| Dec 19, 2025 | Clayton M Magouyrk
Chief Executive Officer
|
Sell | 10.0K | $1.9M |
| Dec 5, 2025 | Maria Smith
Officer
|
Grant | 11.0K | - |
| Oct 28, 2025 | Jeffrey S Berg
Director
|
Sell | 49.4K | $14.0M |
| Oct 23, 2025 | Maria Smith
Officer
|
Sell | 10.0K | $2.8M |
| Oct 21, 2025 | Clayton M Magouyrk
Chief Executive Officer
|
Sell | 40.0K | $11.1M |
| Oct 10, 2025 | Stuart A Levey
Officer
|
Sell | 19.8K | $5.9M |
| Sep 26, 2025 | Naomi O Seligman
Director
|
Sell | 2.2K | $642.0K |
| Sep 26, 2025 | Naomi O Seligman
Director
|
Grant | 1.4K | - |
| Sep 23, 2025 | Michael D Sicilia
Officer
|
Sell | 33.8K | $10.9M |
| Sep 19, 2025 | Jeffrey O Henley
Officer and Director
|
Grant | 46.5K | - |
| Sep 19, 2025 | Stuart A Levey
Officer
|
Grant | 20.9K | - |
| Sep 19, 2025 | Clayton M Magouyrk
Officer
|
Grant | 129.9K | - |
| Sep 19, 2025 | Michael D Sicilia
Officer
|
Grant | 109.2K | - |
| Sep 19, 2025 | Maria Smith
Officer
|
Grant | 17.4K | - |
| Sep 16, 2025 | Michael D Sicilia
Officer
|
Sell | 16.3K | $5.1M |
| Sep 15, 2025 | Jeffrey O Henley
Officer and Director
|
Grant | 19.8K | - |
| Sep 15, 2025 | Stuart A Levey
Officer
|
Grant | 26.3K | - |
| Sep 15, 2025 | Clayton M Magouyrk
President
|
Grant | 61.5K | - |
| Sep 15, 2025 | Michael D Sicilia
Officer
|
Grant | 52.7K | - |
| Sep 15, 2025 | Maria Smith
Officer
|
Grant | 13.2K | - |
| Sep 12, 2025 | Clayton M Magouyrk
President
|
Sell | 21.2K | $6.3M |
| Sep 12, 2025 | William G Parrett
Director
|
Sell | 11.5K | $3.5M |
| Aug 5, 2025 | Michael D Sicilia
Officer
|
Sell | 15.9K | $4.0M |
| Aug 4, 2025 | Jeffrey O Henley
Officer and Director
|
Grant | 25.0K | - |
| Aug 4, 2025 | Clayton M Magouyrk
Officer
|
Grant | 62.5K | - |
| Aug 4, 2025 | Michael D Sicilia
Officer
|
Grant | 183 | $44.2K |
| Aug 4, 2025 | Michael D Sicilia
Officer
|
Grant | 50.0K | - |
| Aug 4, 2025 | Maria Smith
Officer
|
Grant | 3.4K | - |
| Jul 16, 2025 | Naomi O Seligman
Director
|
Sell | 3.3K | $770.7K |
| Jul 15, 2025 | Lawrence Joseph Ellison
Chief Technology Officer
|
Option | 6.5M | $332.3M |
| Jul 9, 2025 | Lawrence Joseph Ellison
Chief Technology Officer
|
Option | 6.0M | $306.8M |
| Jul 7, 2025 | Rona Alison Fairhead
Director
|
Buy | 480 | $112.3K |
| Jul 3, 2025 | Maria Smith
Officer
|
Sell | 10.0K | $2.3M |
| Jun 27, 2025 | Safra A Catz
Chief Executive Officer
|
Sell | 1.3M | $267.2M |
| Jun 27, 2025 | Safra A Catz
Chief Executive Officer
|
Option | 1.3M | $64.4M |
| Jun 26, 2025 | Safra A Catz
Chief Executive Officer
|
Sell | 3.7M | $794.6M |
| Jun 26, 2025 | Safra A Catz
Chief Executive Officer
|
Option | 3.7M | $191.2M |
| Jun 23, 2025 | Safra A Catz
Chief Executive Officer
|
Sell | 3.7M | $764.0M |
| Jun 23, 2025 | Safra A Catz
Chief Executive Officer
|
Option | 3.7M | $188.9M |
| Jun 23, 2025 | Jeffrey O Henley
Officer and Director
|
Grant | 147.0K | - |
| Jun 17, 2025 | Clayton M Magouyrk
Officer
|
Sell | 15.0K | $3.2M |
| Jun 17, 2025 | George Henry Conrades
Director
|
Sell | 8.2K | $1.7M |
| Jun 12, 2025 | Jeffrey O Henley
Officer and Director
|
Sell | 400.0K | $76.2M |
| Jun 12, 2025 | Jeffrey O Henley
Officer and Director
|
Option | 400.0K | $16.1M |
| May 30, 2025 | Awo Ablo
Director
|
Grant | 3.0K | - |
| May 30, 2025 | Jeffrey S Berg
Director
|
Grant | 3.0K | - |
| May 30, 2025 | Michael J Boskin
Director
|
Grant | 3.0K | - |
| May 30, 2025 | Bruce R Chizen
Director
|
Grant | 3.0K | - |
| May 30, 2025 | George Henry Conrades
Director
|
Grant | 3.0K | - |
| May 30, 2025 | Rona Alison Fairhead
Director
|
Grant | 3.0K | - |
| May 30, 2025 | Charles W Moorman IV
Director
|
Grant | 3.0K | - |
| May 30, 2025 | Leon E Panetta
Director
|
Grant | 3.0K | - |
| May 30, 2025 | William G Parrett
Director
|
Grant | 3.0K | - |
| May 30, 2025 | Naomi O Seligman
Director
|
Grant | 3.0K | - |
| May 14, 2025 | Jeffrey S Berg
Director
|
Grant | 12.3K | - |
| May 5, 2025 | Naomi O Seligman
Director
|
Sell | 2.9K | $428.6K |
| May 2, 2025 | Leon E Panetta
Director
|
Sell | 17.5K | $2.6M |
| May 2, 2025 | Leon E Panetta
Director
|
Option | 17.5K | $761.1K |
| Apr 21, 2025 | George Henry Conrades
Director
|
Option | 22.5K | $978.5K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.